Antonio Cuadrado, María Barrio, José Ignacio Fortea, Lidia Amigo, David San Segundo, María Paz Rodriguez‐Cundin, María Henar Rebollo, Roberto Fernandez‐Santiago, Federico Castillo, Maria Achalandabaso, Juan Echeverri, Edward J.
Ankur Jindal – 26 March 2022
Gyongyi Szabo, Mack Mitchell, Craig J. McClain, Srinivasan Dasarathy, Bruce Barton, Arthur J. McCullough, Laura E. Nagy, Aimee Kroll‐Desrosiers, David Tornai, Hyesung Alice Min, Svetlana Radaeva, M. E. Blair Holbein, Lisa Casey, Jennifer Cuthbert – 26 March 2022
Anandini Suri, Dhiren Patel, Jeffery Teckman – 26 March 2022
Tingjie Wang, Chuanrui Xu, Zhijing Zhang, Hua Wu, Xiujuan Li, Yu Zhang, Nan Deng, Ningxin Dang, Guangbo Tang, Xiaofei Yang, Bingyin Shi, Zihang Li, Lei Li, Kai Ye – 26 March 2022
Anandini Suri, Dhiren Patel, Jeffery Teckman – 26 March 2022
Hongxia Cai, Xing Cheng, Xiao‐Ping Wang – 26 March 2022
Fanta Barrow, Xavier S. Revelo – 26 March 2022
Hao Zhou, Xiaomei Wang, Clifford J. Steer, Guisheng Song, Junqi Niu – 25 March 2022 – Hepatitis B virus (HBV) infection is a major risk factor of liver cirrhosis and hepatocellular carcinoma. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) has been used to precisely edit the HBV genome and eliminate HBV through non‐homologous end‐joining repair of double‐stranded break (DSB). However, the CRISPR/Cas9‐mediated DSB triggers instability of host genome and exhibits low efficiency to edit genome, limiting its application.
24 March 2022